Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca, Ethris sign mRNA agreement

by Lisa M. Jarvis
August 28, 2017 | A version of this story appeared in Volume 95, Issue 34

AstraZeneca will pay Ethris roughly $30 million as part of a five-year collaboration to develop RNA therapies for respiratory diseases. Under the pact, Ethris will develop messenger RNA therapies based on its technology, which allows a nonimmunogenic transcript to be delivered into cells. The companies will work on treatments for asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. Since 2013 AstraZeneca has been working with Moderna Therapeutics to develop mRNA-based drugs for cardiovascular, metabolic, and renal diseases.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.